YKYoshiaki Kiso

Yoshiaki Kiso

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yoshiaki Kiso has a total of 172 co-authors. Here are the top co-authors by number of shared publications:

  • Tooru Kimura

    Department of Medicinal Chemistry , Kyoto Pharmaceutical University , Kyoto 607-8412 , Japan

    31 shared publications
  • Yoshio Hayashi

    Department of Medicinal Chemistry, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo 192-0392, Japan

    19 shared publications
  • Youhei Sohma

    Department of Medicinal Chemistry, Center for Frontier Research in Medicinal Science, Kyoto Pharmaceutical University, Yamashina-ku, Kyoto 607-8412, Japan

    11 shared publications
  • Koushi Hidaka

    Department of Medicinal Chemistry, Center for Frontier Research in Medicinal Science, Kyoto Pharmaceutical University, Yamashina-ku, Kyoto 607-8412, Japan

    9 shared publications
  • Taku Yoshiya

    Peptide Institute, Inc. Osaka Japan

    8 shared publications
  • Atsuhiko Taniguchi

    Department of Medicinal Chemistry, Center for Frontier Research in Medicinal Science, 21st Century COE Program, Kyoto Pharmaceutical University, Yamashina-ku, Kyoto, Japan

    7 shared publications

Latest Publications

  • Open Access

    Mitocryptide-2: Identification of Its Minimum Structure for Specific Activation of FPR2–Possible Receptor Switching from FPR2 to FPR1 by Its Physiological C-terminal Cleavages

    by Takayuki Marutani, Kodai Nishino, Tomoyuki Miyaji, Keisuke Kamada, Koji Ohura, Yoshiaki Kiso, Hidehito Mukai

    Mitocryptides are a novel family of endogenous neutrophil-activating peptides originating from various mitochondrial proteins. Mitocryptide-2 (MCT-2) is one of such neutrophil-activating peptides, and is produced as an N-formylated pentadecapeptide from mitochondrial cytochrome b. Although MCT-2 is a specific endogenous ligand for formyl peptide receptor 2 (FPR2), the chemical structure within MCT-2 that is responsible for FPR2 activation is still obscure. Here, we demonstrate that the N-terminal heptapeptide structure of MCT-2 with an N-formyl group is the minimum structure that specifically activates FPR2. Moreover, the receptor molecule for MCT-2 is suggested to be shifted from FPR2 to its homolog formyl peptide receptor 1 (FPR1) by the physiological cleavages of its C-terminus. Indeed, N-terminal derivatives of MCT-2 with seven amino acid residues or longer caused an increase of intracellular free Ca2+ concentration in HEK-293 cells expressing FPR2, but not in those expressing FPR1. Those MCT-2 derivatives also induced β-hexosaminidase secretion in neutrophilic/granulocytic differentiated HL-60 cells via FPR2 activation. In contrast, MCT-2(1–4), an N-terminal tetrapeptide of MCT-2, specifically activated FPR1 to promote those functions. Moreover, MCT-2 was degraded in serum to produce MCT-2(1–4) over time. These findings suggest that MCT-2 is a novel critical factor that not only initiates innate immunity via the specific activation of FPR2, but also promotes delayed responses by the activation of FPR1, which may include resolution and tissue regeneration. The present results also strongly support the necessity of considering the exact chemical structures of activating factors for the investigation of innate immune responses.


  • Toxic Amyloid Tape: A Novel Mixed Antiparallel/Parallel β-Sheet Structure Formed by Amyloid β-Protein on GM1 Clusters

    by Yuki Okada, Kaori Okubo, Keisuke Ikeda, Yoshiaki Yano, Masaru Hoshino, Yoshio Hayashi, Yoshiaki Kiso, Hikari Itoh-Watanabe, Akira Naito, Katsumi Matsuzaki

    The abnormal aggregation of amyloid β-protein (Aβ) is considered central in the pathogenesis of Alzheimer’s disease. We focused on membrane-mediated amyloidogenesis and found that amyloid fibrils formed on monosialoganglioside GM1 clusters were more toxic than those formed in aqueous solution. In this study, we investigated the structure of the toxic fibrils by Aβ-(1–40) in detail in comparison with less-toxic fibrils formed in aqueous solution. The less-toxic fibrils contain in-resister parallel β-sheets, whereas the structure of the toxic fibrils is unknown. Atomic force microscopy revealed that the toxic fibrils had a flat, tape-like morphology composed of a single β-sheet layer. Isotope-edited infrared spectroscopy indicated that almost the entire sequence of Aβ is included in the β-sheet. Chemical cross-linking experiments using Cys-substituted Aβs suggested that the fibrils mainly contained both in-resister parallel and two-residue-shifted antiparallel β-sheet structures. Solid-state NMR experiments also supported this conclusion. Thus, the toxic fibrils were found to possess a novel unique structure.


  • Identification of Highly Potent Human Immunodeficiency Virus Type-1 Protease Inhibitors against Lopinavir and Darunavir Resistant Viruses from Allophenylnorstatine-Based Peptidomimetics with P2 Tetrahydrofuranylglycine

    by Koushi Hidaka, Tooru Kimura, Rajesh Sankaranarayanan, Jun Wang, Keith F. McDaniel, Dale J. Kempf, Masanori Kameoka, Motoyasu Adachi, Ryota Kuroki, Jeffrey-Tri Nguyen, et al.

    The emergence of drug-resistant HIV from a wide-spread anti-viral chemotherapy targeting HIV protease in the past decades is unavoidable and provides a challenge to develop alternative inhibitors. We synthesized a series of allophenylnorstatine-based peptidomimetics with various P3, P2 and P2´ moieties. The derivatives with P2 tetrahydrofuranylglycine (Thfg) were found to be potent against wild type HIV-1 protease and the virus, leading to a highly potent compound 21f (KNI-1657) against lopinavir/ritonavir- or darunavir-resistant strains. Co-crystal structures of 21f and the wild-type protease revealed numerous key hydrogen bonding interactions with Thfg. These results suggest that the strategy to design allophenylnorstatine-based peptidomimetics combined with Thfg residue would be promising for generating candidates to overcome multi-drug resistance.


  • Molecular sieving effects of disk-shaped molecules on reverse osmosis and nanofiltration separation

    by Yoshiaki Kiso, Tatsuo Oguchi, Yuki Kamimoto, Kazuya Makino, Yuki Takeyoshi, Toshiro Yamada


  • New directions for protease inhibitors directed drug discovery

    by Yoshio Hamada, Yoshiaki Kiso

    Proteases play crucial roles in various biological processes, and their activities are essential for all living organisms—from viruses to humans. Since their functions are closely associated with many pathogenic mechanisms, their inhibitors or activators are important molecular targets for developing treatments for various diseases. Here, we describe drugs/drug candidates that target proteases, such as malarial plasmepsins, β‐secretase, virus proteases, and dipeptidyl peptidase‐4. Previously, we reported inhibitors of aspartic proteases, such as renin, human immunodeficiency virus type 1 protease, human T‐lymphotropic virus type I protease, plasmepsins, and β‐secretase, as drug candidates for hypertension, adult T‐cell leukaemia, human T‐lymphotropic virus type I‐associated myelopathy, malaria, and Alzheimer's disease. Our inhibitors are also described in this review article as examples of drugs that target proteases. © 2015 Wiley Periodicals, Inc. Biopolymers (Pept Sci) 106: 563–579, 2016.


  • Open Access

    A membrane extraction method for trace level phosphate analysis

    by Satoshi Asaoka, Yoshiaki Kiso, Masahiro Nagai, Hideo Okamura

    The concentration of phosphate in surface and oligotrophic waters is sometimes below the detection limit of conventional analytical methods. In this work, a membrane extraction method using a hydrophilic PTFE (H-PTFE) membrane filter was developed to detect trace level phosphate. Phosphoantimonyl-molybdenum blue (PAMB) was prepared under conventional conditions. The PAMB was made to react with hexadecyltrimethyl ammonium (HTMA) ions by ultrasonication in an ice bath to form an ion pair of PAMB and HTMA. The ion pair was entrapped on a H-PTFE filter by filtration, and the ion pair on the filter was extracted with CH3CN. When 10 mL of CH3CN was used as the extraction solvent for 100 mL of water sample (10 times of concentration factor), 0.80 μg PO4 L−1 (0.26 μg P L−1) was successfully detected using a conventional spectrophotometer equipped with a 5 cm cell. The total phosphorus could also be detected after oxidation with potassium peroxosulfate.


  • Optimization of plasmepsin inhibitor by focusing on similar structural feature with chloroquine to avoid drug-resistant mechanism of Plasmodium falciparum

    by Takuya Miura, Koushi Hidaka, Yukiko Azai, Keisuke Kashimoto, Yuko Kawasaki, Shen-En Chen, Renato Ferreira de Freitas, Ernesto Freire, Yoshiaki Kiso


  • Advances in the identification of β-secretase inhibitors

    by Yoshio Hamada, Yoshiaki Kiso

    Introduction: Alzheimer's disease (AD), which is characterized by progressive intellectual deterioration, is the most common cause of dementia. β-Secretase (or BACE1) expression is a trigger for amyloid β peptide formation, a cause of AD, and thus is a molecular target for the development of drugs against AD. Many BACE1 inhibitors have been identified by academic and pharmaceutical research groups and a number of advanced technologies in drug discovery have been applied to the drug discovery. Areas covered: The purpose of this review is to present and discuss the methodologies used for BACE1 inhibitor drug discovery via substrate- and structure-based design, high-throughput screening and fragment-based drug design. The authors also review the advantages and disadvantages of these methodologies. Expert opinion: Many BACE1 inhibitors have been designed using X-ray crystal structure-based drug design as well as through in silico screening. Nevertheless, there are serious problems with regards to deciding the best X-ray crystal structure for designing BACE1 inhibitors through computational approaches. There are two prominent configurations of BACE1 but there is still room for improvement. Future developments may make it possible to identify BACE1 inhibitors as potential drug candidates.


  • Synthesis of O‐Acyl Isopeptides

    by Youhei Sohma, Yoshiaki Kiso

    O‐Acyl isopeptides, in which the N‐acyl linkage on the hydroxyamino acid residue (e.g., Ser and Thr) is replaced with an O‐acyl linkage, generally possess superior water‐solubility to their corresponding native peptides, as well as other distinct physicochemical properties. In addition, O‐acyl isopeptides can be rapidly converted into their corresponding native peptide under neutral aqueous conditions through an O‐to‐N acyl migration. By exploiting these characteristics, researchers have applied the O‐acyl isopeptide method to various peptide‐synthesis fields, such as the synthesis of aggregative peptides and convergent peptide synthesis. This O‐acyl‐isopeptide approach also serves as a means to control the biological function of the peptide in question. Herein, we report the synthesis of O‐acyl isopeptides and some of their applications.